Shingles Vaccine Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Global Shingles Vaccine Market Dynamics
Shingles, commonly known as herpes zoster, is a virus that attacks the brain's cranial nerves. It's caused by the varicella zoster virus, which is also responsible for chicken pox. Because the virus can remain dormant in the human body for several years, everyone who has had chicken pox before is at risk of acquiring shingles. According to the Centers for Disease Control and Prevention (CDC), one million cases of shingles were reported in the United States in 2018. Furthermore, the CDC estimates that one out of every three persons in the United States will have shingles at some point in their lives. Shingles risk rises with age, with the majority of cases occurring in people over the age of 50.
Skin rashes, nerve discomfort, eyesight loss, cold, upset stomach, muscle weakness, skin infection, and scarring are some of the symptoms. Antiviral medications such as acyclovir, valacyclovir, and famciclovir are used to treat shingles. These medications aid in reducing the length and intensity of the sickness. Furthermore, analgesics may aid in pain relief.
Merck & Co., Inc. licenced the Zostavax vaccine in 2006, and it is an effective shingles vaccine. The vaccine is indicated for those who are 50 years old or older. The Zostavax vaccination was found to be 64% effective in adults aged 60 to 69 years old in clinical studies. As people get older, their effectiveness decreases, dropping to 41% for those aged 70–79 and 18% for those aged 80 and up. In February 2016, the vaccine was introduced in India at half the price of the US market. In 2015, Zostavax was the sole shingles vaccine on the market, with sales of $749 million.
GlaxoSmithKline (GSK), a global leader in the vaccines business, submitted for FDA clearance of its shingles vaccine, 'Shingrix,' in October 2016. Shingrix has produced better results in clinical trials than Zostavax. In those above the age of 70, the vaccine was 90 percent effective.
Shingles, commonly known as herpes zoster, is a virus that attacks the brain's cranial nerves. It's caused by the varicella zoster virus, which is also responsible for chicken pox. Because the virus can remain dormant in the human body for several years, everyone who has had chicken pox before is at risk of acquiring shingles. According to the Centers for Disease Control and Prevention (CDC), one million cases of shingles were reported in the United States in 2018. Furthermore, the CDC estimates that one out of every three persons in the United States will have shingles at some point in their lives. Shingles risk rises with age, with the majority of cases occurring in people over the age of 50.
Skin rashes, nerve discomfort, eyesight loss, cold, upset stomach, muscle weakness, skin infection, and scarring are some of the symptoms. Antiviral medications such as acyclovir, valacyclovir, and famciclovir are used to treat shingles. These medications aid in reducing the length and intensity of the sickness. Furthermore, analgesics may aid in pain relief.
Merck & Co., Inc. licenced the Zostavax vaccine in 2006, and it is an effective shingles vaccine. The vaccine is indicated for those who are 50 years old or older. The Zostavax vaccination was found to be 64% effective in adults aged 60 to 69 years old in clinical studies. As people get older, their effectiveness decreases, dropping to 41% for those aged 70–79 and 18% for those aged 80 and up. In February 2016, the vaccine was introduced in India at half the price of the US market. In 2015, Zostavax was the sole shingles vaccine on the market, with sales of $749 million.
GlaxoSmithKline (GSK), a global leader in the vaccines business, submitted for FDA clearance of its shingles vaccine, 'Shingrix,' in October 2016. Shingrix has produced better results in clinical trials than Zostavax. In those above the age of 70, the vaccine was 90 percent effective.
Comments
Post a Comment